PSO is a common abbreviation for psoriasis, a chronic autoimmune disease that causes skin cells to build up into raised, scaly patches. It affects roughly 125 million people worldwide, or about 2 to 3 percent of the global population. Psoriasis is not contagious, not caused by poor hygiene, and not simply a cosmetic problem. It is a systemic inflammatory condition with effects that can extend well beyond the skin.
What Happens in the Skin
In healthy skin, new cells form in the deepest layer and gradually rise to the surface over the course of about a month, replacing old cells that shed invisibly. In psoriasis, the immune system sends faulty signals that dramatically speed up this process. Skin cells pile up on the surface faster than the body can shed them, forming thick, raised patches called plaques.
The core problem is an overactive group of immune cells. A type of white blood cell called the Th17 cell plays the dominant role, releasing chemical messengers that drive inflammation and trigger skin cells to multiply at an abnormal rate. Other immune cells, including dendritic cells, neutrophils, and macrophages, form an inflammatory loop that sustains the process. Regulatory cells that would normally calm the immune response are dysfunctional in psoriatic skin, which helps explain why the disease persists and flares repeatedly.
Types of Psoriasis
Psoriasis takes several forms, and more than one type can be present at the same time.
- Plaque psoriasis is by far the most common. It causes dry, raised patches covered with gray or silver scales. On lighter skin these patches tend to appear pink or red; on darker skin they often look brown or gray.
- Guttate psoriasis shows up as small, drop-shaped spots on the trunk, arms, or legs, usually covered by a fine scale. It often appears after a strep throat infection, particularly in children and young adults.
- Inverse psoriasis produces smooth, inflamed patches in skin folds, typically under the breasts, around the groin, and between the buttocks. Because these areas stay moist, the patches lack the typical silvery scale.
- Erythrodermic psoriasis is the rarest and most serious form. It can cover the entire body with a scaly rash that itches or burns intensely and may require emergency medical care.
Causes and Genetic Risk
Psoriasis runs in families, and genetics account for a significant share of who develops it. The gene variant most strongly linked to the disease is called HLA-Cw6. People who carry this variant have roughly five times the odds of developing psoriasis compared to those who don’t. The frequency of this variant differs across populations, found in anywhere from about 10 to 77 percent of psoriasis patients depending on ethnicity.
Genetics alone aren’t enough to cause the disease, though. Most people with a family history never develop psoriasis, and many patients have no known relatives with the condition. It takes an environmental trigger to set the immune system off in someone who is genetically susceptible.
Common Triggers
Flares can be unpredictable, but several well-established triggers increase the chances of one. Physical trauma to the skin, even something as minor as a scratch, sunburn, or vaccination site, can provoke new plaques at the injury location. This response is known as the Koebner phenomenon. Infections, especially strep throat, are a classic trigger for guttate flares. Emotional stress is another reliable aggravator.
Certain medications can also induce or worsen psoriasis. Beta-blockers (used for blood pressure), lithium (used for mood disorders), antimalarial drugs, and some newer cancer immunotherapies all carry documented associations. Stopping systemic or potent topical corticosteroids too quickly can cause a rebound flare that is sometimes more severe than the original outbreak.
Psoriatic Arthritis
Between 7 and 26 percent of people with psoriasis eventually develop psoriatic arthritis, an inflammatory joint condition that can cause permanent damage if left untreated. Skin symptoms usually appear first, sometimes years before joint involvement begins.
The hallmark signs include joint pain and swelling, morning stiffness lasting longer than an hour, fatigue, and difficulty with everyday tasks like getting dressed or brushing teeth. A particularly distinctive feature is dactylitis, where an entire finger or toe swells into what’s often called a “sausage digit.” Neck and lower back pain that worsens with rest and improves with movement can signal spinal involvement, which occurs in a substantial portion of patients. People with more severe skin disease, nail changes (pitting, thickening, or separation from the nail bed), and scalp or groin involvement appear to be at highest risk.
Cardiovascular and Metabolic Risks
Psoriasis is not just skin-deep. The same systemic inflammation that drives plaques also affects blood vessels and metabolism. Patients with psoriasis are up to 50 percent more likely to develop cardiovascular disease than the general population, and this risk climbs with skin severity. People with severe psoriasis face up to three times the odds of a heart attack, 60 percent higher odds of stroke, and 40 percent higher odds of dying from a cardiovascular event.
Coronary imaging studies show that psoriasis patients have about twice the odds of calcium buildup in their coronary arteries, comparable to what’s seen in diabetic patients without psoriasis. They also carry about 15 percent more noncalcified plaque in their coronary arteries, with higher-risk plaque correlating directly to worse skin disease. These findings have shifted the medical view of psoriasis from a skin disorder to a condition that requires attention to heart health as well.
Treatment Approaches
Mild psoriasis is typically managed with topical treatments applied directly to the skin, including corticosteroid creams and vitamin D-based preparations. Phototherapy, which exposes the skin to controlled ultraviolet light, is another option for moderate disease.
For moderate to severe psoriasis, biologic therapies have transformed outcomes over the past two decades. These are injectable medications that target specific parts of the immune pathway driving the disease. The main classes block three different inflammatory proteins: TNF-alpha (the earliest biologic targets), IL-23 (which helps maintain the Th17 cells central to psoriasis), and IL-17 (the downstream chemical messenger most directly responsible for skin cell overproduction). Biologics targeting IL-17 and IL-23 tend to produce the fastest visible improvement. The newest IL-17 inhibitors can bring 50 percent of patients to a major clinical response faster than any other biologic class currently available.
Diet and Lifestyle Factors
Weight management has some of the strongest lifestyle evidence behind it. Obesity is closely linked to psoriasis severity, and clinical trials show that overweight patients who follow a low-calorie diet alongside standard treatment are more likely to see their skin improve than those on treatment alone. One study found that a structured weight-loss program combining a very low-calorie phase with a Mediterranean-style diet reduced psoriasis severity scores by roughly 50 percent.
The Mediterranean diet, rich in fruits, vegetables, whole grains, and healthy fats, has shown an inverse relationship with psoriasis activity in clinical research. Higher adherence to this dietary pattern correlates with lower disease severity. For the subset of patients who test positive for antibodies to gluten (a sign of gluten sensitivity), a gluten-free diet has shown meaningful improvement, with 60 percent of seropositive patients in one study experiencing worsening symptoms after returning to their regular diet.
None of these dietary changes replace medical treatment, but they can serve as a practical complement, particularly for patients whose weight or overall inflammation is contributing to more frequent or severe flares.